A Cure Rate Model with Discrete Frailty on Hodgkin Lymphoma Patients after Diagnosis by Mohseni, Navid et al.
 
NonCommercial 4.0 International License, -is an open access article under the terms of the Creative Commons Attribution  sof Advances in Bioscience sArchive  
15 
Original Article  
A Cure Rate Model with Discrete Frailty on Hodgkin 
Lymphoma Patients after Diagnosis 
 
Navid Mohseni, Ali Akbar Khadem Maboudi 
*, ,
, Ahmadreza Baghestani, Anahita Saeedi 
 










Introduction: Hodgkin lymphoma (HL) is an uncommon cancer of 
lymphocytes, characterized by cancerous Reed-Sternberg cells in an 
inflammatory background. HL is an exceptionally curable disease with 
combination chemotherapy, radiotherapy, or combined modality treatment. 
This analysis aimed to identify significant prognostic factors on the cure rate.  
Materials and Methods: The medical records of 110 patients hospitalized from 
2007 up to 2014 with 18 months follow-up was retrospectively reviewed in 
Taleghani hospital of Tehran, Iran. The survival time was set as the time 
interval between diagnosis and a patient's death from HL. Also, if the cure rate 
was present in survival, data encompasses zero frailty. Thus, using hyper-
Poisson (hP) distribution as discrete frailty, the unobserved heterogeneity and 
random effects were accounted for. 
Results: The estimated cure fraction was 81.2%, which was obtained after 
2717 days (7.4 years). In noncured cases, the mean survival time was 1535 
days (4.2 years). Also, the five and ten-year survival rates were 0.91 and 0.80, 
respectively. After diagnosis, results revealed that patients with age  45, 
hemoglobin  12, WBC  15000, and BMI  30 were associated with poor 
outcome by using simple analysis. More importantly, there is no significant 
difference between males and females in the cure of HL patients. 
Conclusion: As expected, the study indicated that a high proportion of HL 
patients got cured. A cure rate model with discrete frailty utilization provided a 
suitable way to account for heterogeneity among HL patients.  
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     Hodgkin lymphoma (HL), initially called 
Hodgkin’s disease, is a rare monoclonal 
lymphoid neoplasm with high cure rates. 
HL is divided into two distinct categories by 
biological studies: classical Hodgkin 
lymphoma and nodular lymphocyte-
predominant Hodgkin lymphoma (NLP-
HL). Classical Hodgkin lymphoma 
comprises the majority of the subtypes 
(accounting for approximately 95% of all 
HL) [1]. The age-adjusted death rate was 
0.3 per 100,000 men and women per year 
based on 2014–2018 deaths statistics. In  
 
2020, it is estimated that there are 8,480 
new cases of Hodgkin lymphoma, and 970 
people would die from the disease [2]. 
Nevertheless, the cure rate is high in 
patients with HL. Chemotherapy and 
radiation therapy are the two main treatment 
methods, and if both methods are used 
simultaneously, more desirable results are 
to be achieved [3]. This progress in 
achieving a high cure rate is mainly due to 
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the development of clinical and treatment 
methods such as multi-agent chemotherapy 
and radiotherapy improvements [4]. HL 
represents a heterogeneous group of 
malignant lymphoid neoplasms, accounting 
for a significant proportion of cancers 
occurring in kids, teenagers, and young 
adults, which has made the disease with an 
age distribution with two modes and a tip 
incidence in the 15–34-year age group and a 
second in the over 60-year-old group [5]. 
Moreover, HL ranked as the 21st most 
common cancer through accounting for 1% 
of all new cases (approximately 1140 cases 
in 2018) in Iran [6]. 
HL has become a standard to study thriving 
radiotherapy and chemotherapy's long-term 
effects as development in diagnosis and the 
generally young age of patients afflicted. 
Most patients' treatment is chemotherapy 
(usually 2 to 4 cycles), followed by 
radiation to the disease's initial site. ABVD 
as standard chemotherapy treatment 
followed by involved-field irradiation is 
considered the standard care for HL, 
providing an excellent balance of efficiency 
and toxicity. More potent combinations, 
such as the BEACOPP regimen, are being 
investigated, usually in patients with 
unfavorable early-stage HL [7, 8]. Still, 
radiation therapy plays a chief role in the 
treatment of early-stage HL. Currently, 
most patients with HL are managed with 
combined modality programs in which 
radiation therapy is given as stabilization 
method after chemotherapy [7, 9]. 
As a member of the population under study, 
each individual met the event of interest in 
survival analysis studies. In other words, 
one of the main assumptions in survival 
analysis was the homogeneity among 
individuals [10]. Nevertheless, the presence 
of a proportion of entirely cured patients of 
a distinct disease who did not suffer any 
loss, death, or recurrence was not neglected 
as the rapid progression in the biomedical 
and drug industry. These people were 
considered cured patients [11]. If the 
follow-up time was long enough, there were 
cured individuals in the dataset. Therefore, 
the population under study were considered 
a composite of cured patients and 
susceptible, and as such, the application of 
cure rate models was more suitable than the 
classical survival models [12]. Though 
covariates may explain heterogeneity, 
unobserved heterogeneity could be 
observed when significant covariates have 
not been included in the study. Frailty was 
defined as a random, multiplicative factor 
applying to the hazard function to account 
for unobserved heterogeneity among 
individuals [13]. The hyper-Poisson 
distribution (hP) is a flexible distribution 
from the family of discrete distributions 
since it can be over-dispersed or under 
dispersed depending on the value of the 
dispersion parameter [14]. 
 
2. Materials and Methods 
     The data of 110 patients were extracted 
for this analysis after deleting subjects with 
incomplete data and missing observation 
times. For initial examination, patients were 
referred to Taleghani Hospital (affiliated to 
the Shahid Beheshti University of Medical 
Sciences), Tehran, Iran, and then treated by 
first-line therapy at the bone marrow 
transplantation department, from 2007 to 
the end of 2014, with a follow-up of 18 
months. Follow-up time was considered to 
determine patients' survival status who were 
contacted by telephone, and their survival 
conditions were recorded from March 2015 
to August 2016.  
The Patients’ information data in this study 
included sex, white cell counts (WBC), 
hemoglobin (Hb), body mass index (BMI), 
age at the time of diagnosis, survival status, 
and survival time by days. The event 
variable was defined as death from the 
disease; therefore, the survival time was 
calculated by the difference between the 
time of diagnosis and the death of the 
patient. 
In the Kaplan-Meier plot, a long plateau 
with a reasonable follow-up time justifies 
the cure rate models' usage. Also, the frailty 
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approach serves as an appropriate statistical 
modeling method to explain the 
heterogeneity of the data which was caused 
by unobserved covariates. Each patient had 
its frailty, and patients with higher frailty 
were more prone to having the event earlier 
[15]. HL patients cured by first-line therapy 
were considered individuals who did not 
experience the event of interest. In other 
words, the event of interest did not happen 
even after a long period of observation. 
These non-susceptible individuals, called 
cured patients, encompass zero frailty [13, 
16]. In this situation, models induced by 
frailty with a non-negative and continuous 
distribution were not considered as proper 
anymore. Hence, discrete frailty was 
essential to model the cured patients 
accurately. Hyper-Poisson distribution (hP) 
was introduced for the first time by 
Bardwell and Crow in 1964 for modeling 
the count data. The important characteristic 
of hP is the flexibility of this distribution, 
which indicates that the Poisson regression 
model's equidispersion assumption is not a 
limitation anymore [14]. Generally, the 
Weibull model can be an adequate 
alternative for baseline distribution with  
and  as shape and scale parameters, 
respectively [17]. The frequency for 
categorical variables was used to summarize 
demographic and prognostic variables in the 
population's study. Then, simple analysis 
for the effect of variables on the cure 
fraction was evaluated. This study was 
conducted after approval of the Ethics 
Committee of Shahid Beheshti University 
of Medical Science (code: 
IR.SBMU.RETECH.REC.1396.966). All 
statistical analyses were performed by R 
programming language version 4.0.1 
(packages: dplyr, ggplot2, survival, stats), 
and the p-value < 0.05 were considered as 
the level of statistical significance. 
 
3. Results 
     Of 110 individuals who were diagnosed 
with Hodgkin lymphoma, 47.2% were men, 
and 52.8% were women. At the time of 
diagnosis, 8.1% of patients were greater 
than or equal to 45 years old, and 91.9% 
were less than 45 years old. While 94.5% of 
HL patients had WBC more than 
15000/mm
3
, 5.5% had less than 
15000/mm
3
. Results of descriptive statistics 
of subjects based on sex, age, WBC, Hb, 
and BMI were presented in Table 1.  
After diagnosis, 11% of patients died from 
the disease. The mean survival time for 
these uncured patients was 1535 days (95% 
confidence interval [CI], 699-2371).   
 
Table 1. Descriptive Statistics of variables 
Variables Number of patients Percentage 
Age  
Age   45 
















BMI  30 









WBC  15000 
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The 5-year and 10-year survival rates were 
91.5% (95% CI: 85.5 - 97.9), 80.1% (95% 
CI: 70.0 - 91.8), respectively. From the 
Kaplan-Meier plot in Figure 1, a large 
proportion of patients had not experienced 
the death within 2717 days (approximately 
eight years) after diagnosis.  
In the next step, hP distribution was used as 
discrete frailty to estimate the cure rate. The 
estimated cure fraction of the model by the 
usage of hP was 81.2%. The factors, as 
mentioned earlier, had been examined 
independently. Hb (p-value: 0.041), age (p-
value < 0.001), BMI (p-value < 0.001), and 
WBC (p-value: 0.007) were independently 
significant which means that except for the 
sex (p-value: 0.197), all considered 
variables had a significant effect on the 
healing of HL patients after diagnosis.  
 
 
Figure 1. Kaplan-Meier curve for the population of the study 
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Figure 2. Kaplan-Meier curves for variables of the study 
 
The simple analysis results are presented in 
table 2 via using the maximum likelihood 
method for each level of the risk factors. As 
was shown, the cure rate for patients more 
than or equal to 45 years old was 40.9%, 
while for patients younger than 45, it was 
84.5%. Cure rate falls from 78.7% to 71.4% 
for patients with WBC less than 15000/mm
3
 
compared to patients who had WBC more 
than 15000/mm
3
. The hP cure rate for 
patients with less than or equal to 12 (g/dL) 
of Hb was 77.9%. In other words, patients 
with a low level of Hb had less cure rate. It 
is crucial to note that sex had no significant 
effect on the cure of patients. Finally, the 
cure rate for patients with a BMI of less 
than 30 was 84.5%, while for patients with 
more than or equal to 30 was 76.8%.
Table 2. hP Cure Rate for Risk Factors in Simple Analysis     




    Age  45 






0.409 1.38 (0.04) 
0.845 -  
Sex 
    Male 





- 0.06 (0.48) 
- -  
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*Significance at the 5% level **Reference Category ***Standard Error 
 
4. Discussion 
     With the advancement of treatment 
methods like chemotherapy or radiotherapy 
in recent years, it is reasonable to expect 
patients to gain high cure rates. When the 
death from HL was considered as the 
outcome of the study, age greater than or 
equal to 45 years old, low Hb (g/dL), high 
level of WBC, and BMI were factors of 
poor outcome, independently. In 2018, 
Brockelmann et al. studied the survival of 
HL patients to a great extent; results of 
many randomized and controlled trials, 
meta-analyses, prospective or retrospective 
studies were evaluated [18]. In the end, the 
five-year survival of patients with Hodgkin 
lymphoma was obtained 95%. In Iran, the 
probability of survival for HL patients 
demonstrated that the five- and 10-year-
survival rates were 65 and 61.3 percent, 
respectively [19]. In 2015, through the 
analysis of long-term survival and cure 
fractions of Hodgkin’s Disease patients, 
Bouliotis and Bessell obtained the cure 
fraction 75% for the 1993-2002 cohort [20].   
The International Prognostic Score (IPS-7) 
serves as one of Hodgkin's lymphoma's 
most broadly risk stratification index [21]. 
Biologically, the factors included in the 
prognostic score are reasonable and 
practical. Age ≥ 45 years and male sex 
independently associated with a more 
unsatisfactory outcome of Hodgkin's 
lymphoma accompanied by hemoglobin < 
10.5 g/dL, WBC count ≥ 15000/mm
3
, 
lymphocyte count < 600/mm
3
, albumin < 40 
g/dL. According to the number of risk 
factors, patients who were in the analysis 
and were treated between 1983 and 1992 
represent different freedom from disease 
progression rates. Patients with five or more 
risk factors were compared with patients 
with no risk factor. The difference was 
significant in a way that the former group 
had a freedom from disease progression rate 
of 42%, and the latter group had 84%. 
However, due to the enhanced outcomes 
with current therapy, recent studies suggest 
that the discriminating impact of the IPS-7 
has reduced [22]. In the present study, age 
was significant in the cure fraction of the 
patients. Patients older than 45 had less hP 
cure rate than patients with less than 45. 
Likewise, Hasenclever et al. also 
demonstrated that age was a significant 
factor in the survival of the HL patients so 
that patients more than 45 years-old had less 
survival probability [23]. Due to improved 
outcomes with contemporary treatment 
methods, Diefenbach et al. tried to replace 
IPS-7 with IPS-3, which finally concluded 
that age, Hb, and stage are significant 
factors on the HL patients [22]. Although 
being male was considered as a significant 
factor in survival by IPS-7, in this study, 
sex had no significant effect on the cure of 
patients at 5% level of significance. In one 
study on head and neck lymphoma in an 
Iranian population, the difference between 
gender was significant in HL patients, 
where women had more survival time [24]. 
WBC 
    WBC  15000 






0.714 0.38 (0.14) 
0.787 -  
Hemoglobin 
    Hemoglobin  12 
  0.041
* 
0.779 5.46 (2.68) 
    Hemoglobin  12
** 0.999 -  
BMI 
    BMI  30 







0.768 0.49 (0.08) 
0.845 -  
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Based on the disease's high stage, absolute 
lymphocyte count, male gender, and age ≥ 
45, another defined risk group has been 
confirmed [25]. However, the male gender 
was not significant in the study by Straus et 
al [26]. HL is a type of cancer that affects 
specialized white blood cells called 
lymphocytes. WBC was a significant factor 
in the present study when WBC  
15000/mm
3
 aligned with IPS-7 [21]. 
According to the study by Hohaus et al., 
anemia is present at diagnosis in 
approximately 40% of patients with HL 
[27]. Anemia was defined as Hb level <12 
g/dl in this study and was an independently 
significant factor in patients' cure. These 
findings, aligned with the present study, 
clarify the importance of Hb in patients with 
HL as they all emphasized the adverse 
effect of low Hb on the cure rate. However, 
it is essential to note that pregnancy can 
affect the Hb results, which was not 
controlled in our study and should be 
considered in further studies [28]. Obesity 
can modify the immune function and thus 
may increase the risk of Hodgkin's 
lymphoma (HL). Renehan et al., by 
studying obesity and Hodgkin lymphoma's 
risk, suggests a positive association between 
body mass index (BMI) and HL [29]. Also, 
according to the study by Keegan et al., in 
young adult women, the higher body mass 
index levels were associated with increased 
HL risk compared to older women. [30]. 
The primary encountering limitation of this 
study was a low number of HL patients due 
to the rareness of the disease; hence, 
research with more sample size is suggested 
for further studies. 
 
5. Conclusion 
     This paper proposed a model for 
accommodating long-term survival data 
obtained from a discrete frailty model by 
assuming hyper-Poisson distribution. Age  
45, hemoglobin  12, WBC  15000, and BMI 
 30 were associated with the cure of HL 
patients after diagnosis when the event of 
interest was a death. 
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